Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. - Wikidata - wikimedia - TriplyDB

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

http://www.wikidata.org/entity/Q37228327

about

UBXD Proteins: A Family of Proteins with Diverse Functions in Cancer Triplet combinations in relapsed/refractory myeloma: update on recent phase 3 trials.Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment.Carfilzomib boosted combination therapy for relapsed multiple myeloma Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (ERK1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed/refractory multiple myeloma with del(17p).Gene Expression Profiles in Myeloma: Ready for the Real World?Insights on Genomic and Molecular Alterations in Multiple Myeloma and Their Incorporation towards Risk-Adapted Treatment Strategy: Concise Clinical Review.Optimizing therapy for del(17p) multiple myeloma.The proteasome and proteasome inhibitors in multiple myeloma.Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.The effect of novel therapies in high-molecular-risk multiple myeloma.Triplet vs. doublet drug regimens for managing multiple myeloma.Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma.An overview of the role of carfilzomib in the treatment of multiple myeloma.Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASP Potential of oncolytic viruses in the treatment of multiple myeloma.Resveratrol Sensitizes Carfilzomib-Induced Apoptosis via Promoting Oxidative Stress in Multiple Myeloma Cells.Short overview on the current standard of treatment in newly diagnosed multiple myeloma.Efficacy and safety of carfilzomib in relapsed and/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials.CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

P2860

Q28069036-FDB1C518-ADF9-4ADA-BFD5-FCBE80D0D550 Q30238893-300AF98F-08ED-4A9E-BC06-A095B3978512 Q33572252-A517967F-21C3-469E-9C82-150F93FA73F7 Q37652953-AE14BF86-77D5-4050-B056-D8B4FDDE50DC Q38672091-D53B175C-D12D-4C95-B6E4-676A68CBEE67 Q38756800-A40EB350-F0A3-48CD-BFDA-2881C35A83B3 Q38757067-2C2392ED-1DBF-4F66-9F20-6929B1DABDB1 Q41969924-8E4BC22E-89DB-489E-B1D1-59EF3B28E021 Q42365345-D61F97B2-5066-428C-A740-0E78D446D3E6 Q43847809-B5987049-F903-4AA8-93EE-A0F713F9E342 Q47095937-127EC0E3-C0AF-4A21-98F1-B22237FF716B Q47153439-D6233F7C-9D57-4BBB-ADC3-8B7A2124C032 Q47339695-1FC925D0-F997-42D2-A5FC-9B05D004461D Q47348957-08FF9ADC-9804-4D11-90C8-93F30B1877BC Q47375990-3B16BCAC-59F5-43FC-9D38-541B2B22C2A6 Q47770089-FF3E41D2-FBD6-47E6-BA62-85743380D333 Q48373422-0CD45B4E-236F-4F23-B049-D0D6CB57B32E Q50035012-C0ECD861-AFC1-473F-B5C8-7136330345A7 Q52609413-BBB93E77-E338-49D4-A220-A03F931297CF Q52674773-A11AF188-74D2-4E08-A02B-E2E2D58FB3E2 Q54960980-F7566EDD-0BBD-477E-84E9-EFA122901F75 Q55091245-7DD95A90-2EB6-41D7-98B9-9D9684558CFF Q55279720-EBE9AAD1-9811-41CF-AE65-5DBB4274C234 Q57801281-B2AC5D7F-A27E-464E-9147-B5FBE10916E3 Q58560605-1C6C9227-ACDC-4E79-95BA-8074120C89FC

P2860

Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma.

http://www.wikidata.org/entity/Q37228327

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 July 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Carfilzomib significantly impr ...... patients in multiple myeloma.

@en

Carfilzomib significantly impr ...... patients in multiple myeloma.

@nl

type

label

Carfilzomib significantly impr ...... patients in multiple myeloma.

@en

Carfilzomib significantly impr ...... patients in multiple myeloma.

@nl

prefLabel

Carfilzomib significantly impr ...... patients in multiple myeloma.

@en

Carfilzomib significantly impr ...... patients in multiple myeloma.

@nl

P1433

Q37228327-BB666A17-6650-4A2E-A90F-6A5812498166

P1476

Q37228327-19384AFB-A9BF-4B5D-932E-462E996D232F

P2093

Q37228327-12186792-88BD-46CA-B746-DD5FB2F1FF08

Q37228327-1246F117-3AA3-414C-B168-D11CD94C3A01

Q37228327-2320F995-4DAD-46E1-87AA-E6BCAC2CFA18

Q37228327-306D6240-7C8C-46D2-8A1A-29E3738AA3F6

Q37228327-32D68A23-F5E4-4794-8D13-EB026E0B0EE3

Q37228327-3B23FA5A-1712-4642-9AB3-66402C392393

Q37228327-3E31A72B-D044-4DF4-A15F-BB1CA6B39A39

Q37228327-65DFE0DB-0176-4B0C-AE72-632F078D8314

Q37228327-8B2B1983-5388-4B5B-9D8B-03D86D4D3BF9

Q37228327-A385A208-AAA1-4861-A1E4-E30D5572377C

P2860

Q37228327-0D433FEC-FDC6-4829-8705-812ED0952B20

Q37228327-16F5789B-4DA7-4C83-BA7F-615CA0774CDC

Q37228327-2C9639F4-1A3A-49B4-A45A-C51307BF4A27

Q37228327-341A46A5-E089-4495-9025-7A3718876B7A

Q37228327-3CC04812-F934-4689-9EE8-4CE2E3179BC3

Q37228327-407B4C44-8B07-40F2-898A-B9D3271F08DA

Q37228327-45D33E5D-4FC6-4604-BFE9-C7720EFA3453

Q37228327-4B4759EE-5E69-45C6-83AC-0AB00FB608F0

Q37228327-61137EE0-B9F9-44BD-823C-90FF3DF3367D

Q37228327-88F6685F-F8D7-4828-9B95-1910E48EDF79

P304

Q37228327-977241C0-B425-4C58-AF61-81FFD59E9D17

P31

Q37228327-73BA0835-0A13-49A4-9D52-63B2CA20B85F

P356

Q37228327-3A2D17A4-CCD6-4284-8040-371120ABCCE1

P407

Q37228327-94015A25-F8F6-482C-980F-ACE3FEF85DF3

P433

Q37228327-9062FF6B-15C8-439E-AE88-1B45487BA64B

P478

Q37228327-4A69D0FC-7757-4EE8-BE5F-963EC692B912

P50

Q37228327-02F2384B-8805-40BD-A65A-04C9FED47994

Q37228327-0C27B1A2-83DF-41CE-99A9-3804535132E5

Q37228327-39B73153-5707-4E1C-AB86-B5A365F14CFE

Q37228327-4DB29B56-C1A0-4580-9579-11A9204E0D81

Q37228327-571B0581-74BB-495B-8E1B-30F18CCC944F

Q37228327-61044C4C-7D28-4D4E-928C-9E9B98665511

Q37228327-74FE38F6-4EAF-4E80-94F6-7DEDEEB20F82

Q37228327-85F1FA79-D93E-4E7D-827E-FC91C4D6B28C

Q37228327-BCF03C20-1A51-4350-8139-A2CDB209CC03

P577

Q37228327-9287D6D9-7F56-4DCC-B5CC-CB3191F66CDC

P698

Q37228327-F7B1F85A-8ADD-45FB-B7F2-5D6222BD3C1B

P921

Q37228327-9BE84228-1DE2-4FB1-BBD2-3D8ADF9F440E

P932

Q37228327-1E52E1BD-071C-41E7-B486-083334F41CB1

P356

BLOOD-2016-03-707596

P1433

P1476

Carfilzomib significantly impr ...... k patients in multiple myeloma

@en

P2093

A Keith Stewart

http://www.w3.org/2001/XMLSchema#string

Andrzej Jakubowiak

http://www.w3.org/2001/XMLSchema#string

David Siegel

http://www.w3.org/2001/XMLSchema#string

Dina Ben-Yehuda

http://www.w3.org/2001/XMLSchema#string

Georgi Mihaylov

http://www.w3.org/2001/XMLSchema#string

Jiri Minarik

http://www.w3.org/2001/XMLSchema#string

Laura Rosiñol

http://www.w3.org/2001/XMLSchema#string

Maria-Victoria Mateos

http://www.w3.org/2001/XMLSchema#string

Michael Wang

http://www.w3.org/2001/XMLSchema#string

Mihaela Obreja

http://www.w3.org/2001/XMLSchema#string

P2860

New criteria for response assessment: role of minimal residual disease in multiple myeloma

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.

Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone.

Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du myélome experience.

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Treatment outcomes in patients with relapsed and refractory multiple myeloma and high-risk cytogenetics receiving single-agent carfilzomib in the PX-171-003-A1 study.

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

P304

1174-1180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2016-03-707596

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P50

Meletios A. Dimopoulos

Herve Avet-Loiseau

Antonio Palumbo

Philippe Moreau

Ruben Niesvizky

P577

2016-07-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27439911

http://www.w3.org/2001/XMLSchema#string

P921

P932

5009511

http://www.w3.org/2001/XMLSchema#string